Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR (808) 877-3351 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-06510 MAUI LAND & PINEAPPLE COMPANY, INC. ...

Exhibit 99.1 Seritage Growth Properties Reports First Quarter 2025 Operating Results New York – May 15, 2025 – Seritage Growth Properties (NYSE: SRG) (the "Company"), a national owner and developer of retail, residential and mixed-use properties today reported financial and operating results for the three months ended March 31, 2025. "The Company's strategy following the completion of a smooth CEO transition remains the same. We will continue to pursue our Plan of Sale with the priority of repaying our rema ...

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 001-41104 VOLATO GROUP, INC. (Exact name of Registrant as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q (State or o ...

For the Transition Period From to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as Specified in its Charter) | Nevada | 511210 | 85-3651036 | | --- | --- | --- | | (State or Other Jurisdiction of | (Primary Standard Industrial | (Internal Revenue Service | | Incorporation or Organization) | Classification Code Number) | Employer Identification Number) | | 10557-B Jefferson Blvd, Culver City, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission File Number: 1-11398 CPI AEROSTRUCTURES, INC. (Registrant's telephone number including area code) Securities registered pursuant to Se ...

Financial Performance - The company incurred a net loss of $2,693,100 for the nine months ended March 31, 2025, and a cumulative net loss of $40.5 million since its incorporation on November 14, 2017[92]. - Revenue for the three months ended March 31, 2025, was approximately $31,000, down from $34,000 for the same period in 2024, and revenue for the nine months ended March 31, 2025, was approximately $55,000 compared to $139,000 in 2024[112]. - The net loss for the three months ended March 31, 2025, was approximately $663,000, a decrease of about 53% compared to a net loss of approximately $1.4 million for the same period in 2024[123]. - For the nine months ended March 31, 2025, the net loss was approximately $2.7 million, which is about 16% lower than the $3.2 million loss for the same period in 2024[123]. Cash and Financing - As of March 31, 2025, the company's cash and cash equivalents totaled $2,858,963, an increase from $2,071,016 as of June 30, 2024[101][107]. - The company has raised net proceeds of approximately $11,760,000 from private placement financing transactions from its incorporation to September 30, 2020[97]. - The company has plans to generate cash through financing transactions, including offerings of common stock, but these plans are subject to market conditions and uncertainty[94][105]. Expenses - General and administrative expenses for the three months ended March 31, 2025, were approximately $428,000, a decrease from $1,135,000 in the same period in 2024[117]. - Technology and content development expenses for the nine months ended March 31, 2025, were approximately $524,000, down from $889,000 for the same period in 2024[119]. - Sales and marketing expenses for the three months ended March 31, 2025, were approximately $118,000, compared to $139,000 for the same period in 2024[121]. - Interest income for the nine months ended March 31, 2025, was approximately $53,000, down from $148,000 for the same period in 2024[122]. - Capital asset additions for the nine months ended March 31, 2025, were $292,200, compared to $228,000 for the same period in 2024, indicating an increase of approximately 28%[124]. Compliance and Internal Controls - The Company received a Nasdaq deficiency letter on November 26, 2024, due to non-compliance with the Stockholders' Equity Requirement of $2,500,000[125]. - On January 10, 2025, the Company submitted a plan to regain compliance and believed it had regained compliance following a public offering[126]. - The Company reported material weaknesses in its internal controls over financial reporting, which could lead to potential misstatements in financial statements[130][131]. - Management identified deficiencies in controls related to journal entries and stock compensation expense calculations[132]. - The Company plans to document processes and controls to address the identified material weaknesses and improve internal control effectiveness[136]. - There were no changes in internal control over financial reporting that materially affected the Company during the period ended March 31, 2025[135]. - The Company intends to take all reasonable measures to maintain compliance with Nasdaq Listing Rules[127]. Business Development - The company is focusing on developing AI-powered B2B and B2C solutions, with the NurseMagic app being a key product that has gained traction[114].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number 001-41219 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CSLM ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-1602789 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41219 CSLM ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-1602789 (State or ...